Buclin T - Search Results

1

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Marzolini C, et al. Among authors: buclin t. AIDS. 2001 Jan 5;15(1):71-5. doi: 10.1097/00002030-200101050-00011. AIDS. 2001. PMID: 11192870

2

[Acquired factor V inhibitor treated with intravenous immunoglobulins].

Buclin T, Schmidt PM, Hauert J, Winkel L, Chapuis G, Bachmann F. Buclin T, et al. Schweiz Med Wochenschr. 1992 Dec 26;122(51-52):1968-70. Schweiz Med Wochenschr. 1992. PMID: 1475662 French.

3

Renal effects of nimesulide in furosemide-treated subjects.

Steinhäuslin F, Munafo A, Buclin T, Macciocchi A, Biollaz J. Steinhäuslin F, et al. Among authors: buclin t. Drugs. 1993;46 Suppl 1:257-62. doi: 10.2165/00003495-199300461-00066. Drugs. 1993. PMID: 7506186

4

Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide.

Biollaz J, Munafo A, Buclin T, Gervasoni JP, Magnin JL, Jaquet F, Brunner-Ferber F. Biollaz J, et al. Among authors: buclin t. Eur J Clin Pharmacol. 1995;47(5):455-60. doi: 10.1007/BF00196861. Eur J Clin Pharmacol. 1995. PMID: 7720769 Clinical Trial.

5

Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method.

Buclin T, Pechère-Bertschi A, Séchaud R, Décosterd LA, Munafo A, Burnier M, Biollaz J. Buclin T, et al. J Clin Pharmacol. 1997 Aug;37(8):679-92. doi: 10.1002/j.1552-4604.1997.tb04355.x. J Clin Pharmacol. 1997. PMID: 9378840 Clinical Trial.

6

Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers.

Rousso P, Buclin T, Nussberger J, Brunner-Ferber F, Brunner HR, Biollaz J. Rousso P, et al. Among authors: buclin t. J Cardiovasc Pharmacol. 1998 Mar;31(3):408-17. doi: 10.1097/00005344-199803000-00012. J Cardiovasc Pharmacol. 1998. PMID: 9514186 Clinical Trial.

7

Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements.

Decosterd LA, Bélaz N, Appenzeller M, Maghraoui A, Rousso P, Buclin T, Biollaz J. Decosterd LA, et al. Among authors: buclin t. Ren Fail. 1998 Mar;20(2):311-7. doi: 10.3109/08860229809045116. Ren Fail. 1998. PMID: 9574457

8

Determination of trace lithium in human erythrocytes by electrothermal atomic-absorption spectrometry with pyrocoated graphite tubes and integrated platform.

Decosterd LA, Buclin T, Dafflon M, Leeman C, Bélaz N, Magnin JL, Biollaz J. Decosterd LA, et al. Among authors: buclin t. J Pharm Pharmacol. 1998 Jun;50(6):693-701. doi: 10.1111/j.2042-7158.1998.tb06907.x. J Pharm Pharmacol. 1998. PMID: 9680083

9

Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers.

Eap CB, Schnyder C, Besson J, Savary L, Buclin T. Eap CB, et al. Among authors: buclin t. Clin Pharmacol Ther. 1998 Jul;64(1):52-7. doi: 10.1016/S0009-9236(98)90022-4. Clin Pharmacol Ther. 1998. PMID: 9695719

10

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.

Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F. Marzolini C, et al. Among authors: buclin t. Cancer Chemother Pharmacol. 1998;42(6):433-40. doi: 10.1007/s002800050842. Cancer Chemother Pharmacol. 1998. PMID: 9788568 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results